The effect of anemia management on chronic renal failure progression

Ghobrial, Emad E.; Salama, Khalid M.; Shiba, Maha F; Shafae, Naglaa H. El

doi:10.1016/j.epag.2013.04.008

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, an absolute or relative deficiency in erythropoietin (EPO) can cause renal anemia. 22,23 Anemia can lead to heightened incidences of cardiovascular 24−26 events in patients with CKD and reduce their quality of life. DOPPS studies suggested that in cases where hemoglobin was administered to patients receiving hemodialysis (hemoglobin, Hb), the mortality and hospitalization rates decreased 10% and 12%, respectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A promising materials approach to combatting renal hyperphosphatemia:Fe(II)-montmorillonites

Yuan¹,

Qin²,

Qiao³

et al. 2017

Turk J Chem

View full text Add to dashboard Cite

Abstract:The objective of the current effort was to determine the efficacy of Fe(II)-montmorillonite (Fe(II)-MMT)as an adjuvant for specific targeted adsorption of phosphate. Specifically, Fe(II)-MMT was studied to combat hyperphosphatemia and anemia arising from chronic renal failure. The adsorption of phosphate over time, pH, and initial concentration was studied. The systems were characterized by X-ray diffraction (XRD), Raman, and zeta potential.The experimental results demonstrated the adsorption time was set to 140 min to achieve maximum adsorption efficiency. It was thus found that the maximum adsorption was at pH 3.0. In addition, it reached equilibrium when the initial phosphate concentration was at 60 mg/L while the maximum adsorption capacity was 5.75 mg of phosphate/g of Fe(II)-MMT. On the other hand, adsorption isotherms showed that the Langmuir model was better than the Freundlich model. This means that the adsorption of the phosphate on Fe(II)-montmorillonites was monolayer adsorption, and the phosphate was successfully adsorbed either onto the surface or intercalated within interlayer volume. Live experiments supported the ability of Fe (II)-MMT to control hyperphosphatemia and treat chronic renal failure.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%